IPA Stock Forecast 2025-2026
Distance to IPA Price Targets
IPA Price Momentum
🤔 Considering ImmunoPrecise (IPA)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Latest IPA Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, IPA has a bullish consensus with a median price target of $5.00 (ranging from $3.00 to $7.00). Currently trading at $0.38, the median forecast implies a 1,199.0% upside. This outlook is supported by 2 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Swayampakula Ramakanth at HC Wainwright & Co., projecting a 1,718.7% upside. Conversely, the most conservative target is provided by Robert Wasserman at Benchmark, suggesting a 679.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
IPA Analyst Ratings
IPA Price Target Range
Latest IPA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for IPA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 14, 2025 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $7.00 |
| Dec 11, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $7.00 |
| Sep 17, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $9.00 |
| Aug 14, 2024 | Benchmark | Robert Wasserman | Speculative Buy | Maintains | $3.00 |
| Jul 30, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $9.00 |
| Mar 15, 2024 | Benchmark | Robert Wasserman | Speculative Buy | Reiterates | $5.00 |
| Mar 15, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $9.00 |
| Sep 18, 2023 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $9.00 |
| Jul 12, 2023 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $9.00 |
| Jul 11, 2023 | Benchmark | Robert Wasserman | Speculative Buy | Reiterates | $7.00 |
| Mar 21, 2023 | Benchmark | Robert Wasserman | Speculative Buy | Maintains | $7.00 |
| Mar 17, 2023 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $9.00 |
| Dec 2, 2022 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Initiates | $9.00 |
| Dec 31, 2021 | Benchmark | Buy | Initiates | $0.00 | |
| Oct 25, 2021 | Benchmark | Buy | Initiates | $0.00 |
ImmunoPrecise Antibodies Ltd. (IPA) Competitors
The following stocks are similar to ImmunoPrecise based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
ImmunoPrecise Antibodies Ltd. (IPA) Financial Data
ImmunoPrecise Antibodies Ltd. has a market capitalization of $17.61M with a P/E ratio of -0.4x. The company generates $16.74M in trailing twelve-month revenue with a -115.9% profit margin.
Revenue growth is -0.4% quarter-over-quarter, while maintaining an operating margin of -46.4% and return on equity of -65.9%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
ImmunoPrecise Antibodies Ltd. (IPA) Business Model
About ImmunoPrecise Antibodies Ltd.
Biotechnology company specializing in custom antibodies.
The company generates revenue by offering a wide range of custom antibody development and research services to academic institutions, pharmaceutical companies, and research organizations. By utilizing advanced technologies, ImmunoPrecise helps accelerate the drug development process, thereby creating value for its clients in the biopharmaceutical sector.
Headquartered in British Columbia, Canada, ImmunoPrecise is involved in significant research areas, including oncology, neuroscience, and infectious diseases. Its collaborations and focus on precision medicine position it as a key player in the biotechnology market, contributing to innovations in therapeutic development and drug discovery.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
72
CEO
Dr. Jennifer Lynne Bath Ph.D.
Country
Canada
IPO Year
1996
Website
www.ipatherapeutics.comImmunoPrecise Antibodies Ltd. (IPA) Latest News & Analysis
ImmunoPrecise Antibodies Ltd. (IPA) has formed a strategic partnership with a major biotech firm to develop Antibody-Drug Conjugates and bispecific antibodies for cancer treatment.
The partnership enhances ImmunoPrecise's capabilities in cancer treatment, potentially increasing its market value and attracting investor interest in its innovative drug development.
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) has rescheduled its Q3 Fiscal 2025 financial results release to March 28, 2025, with an earnings call at 10:30 am ET the same day.
The rescheduling of ImmunoPrecise Antibodies' earnings release may signal potential issues in financial reporting, impacting investor confidence and stock performance.
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) will host a conference call on March 13, 2025, at 10:30 am ET to discuss Q3 fiscal 2025 results and business highlights.
ImmunoPrecise's upcoming conference call will reveal quarterly results and business updates, impacting investor sentiment and stock performance based on financial health and growth prospects.
IPA and RIBOPRO Partner to Advance mRNA-Driven Antibody Discovery, Unlocking New Frontiers in Immunotherapy
17 days agoImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) has announced a strategic collaboration with RIBOPRO to enhance therapeutic antibody discovery using mRNA and lipid nanoparticle technologies.
The collaboration between ImmunoPrecise Antibodies and RIBOPRO enhances their capabilities in antibody development, potentially leading to innovative therapies and increased market competitiveness, influencing stock performance.
ImmunoPrecise Antibodies (NASDAQ: IPA) announced leadership changes, appointing Kamil Isaev to its Board and Joseph Scheffler as Interim CFO, while Chris Buyse will depart from the Board.
Leadership changes can signal strategic shifts and impact a company's direction, affecting investor confidence and stock performance. New appointments may influence future growth and innovation.
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) has received approval to transfer to the Nasdaq Capital Market, gaining an extra 180 days until August 18, 2025, to meet the $1.00 minimum bid price requirement.
ImmunoPrecise Antibodies' transfer to the Nasdaq Capital Market provides a 180-day extension to meet the $1.00 share price requirement, potentially stabilizing its stock and attracting investors.
Frequently Asked Questions About IPA Stock
What is ImmunoPrecise Antibodies Ltd.'s (IPA) stock forecast for 2025?
Based on our analysis of 3 Wall Street analysts, ImmunoPrecise Antibodies Ltd. (IPA) has a median price target of $5.00. The highest price target is $7.00 and the lowest is $3.00.
Is IPA stock a good investment in 2025?
According to current analyst ratings, IPA has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.38. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for IPA stock?
Wall Street analysts predict IPA stock could reach $5.00 in the next 12 months. This represents a 1,199.0% increase from the current price of $0.38. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is ImmunoPrecise Antibodies Ltd.'s business model?
The company generates revenue by offering a wide range of custom antibody development and research services to academic institutions, pharmaceutical companies, and research organizations. By utilizing advanced technologies, ImmunoPrecise helps accelerate the drug development process, thereby creating value for its clients in the biopharmaceutical sector.
What is the highest forecasted price for IPA ImmunoPrecise Antibodies Ltd.?
The highest price target for IPA is $7.00 from Swayampakula Ramakanth at HC Wainwright & Co., which represents a 1,718.7% increase from the current price of $0.38.
What is the lowest forecasted price for IPA ImmunoPrecise Antibodies Ltd.?
The lowest price target for IPA is $3.00 from Robert Wasserman at Benchmark, which represents a 679.4% increase from the current price of $0.38.
What is the overall IPA consensus from analysts for ImmunoPrecise Antibodies Ltd.?
The overall analyst consensus for IPA is bullish. Out of 3 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $5.00.
How accurate are IPA stock price projections?
Stock price projections, including those for ImmunoPrecise Antibodies Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
